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In the 1970s, Pseudomonas aeruginosa was recognized as the micro-
organism associated with lethal bacteremia in the neutropenic host. Cur-
rently, P aeruginosa is a highly virulent micro-organism recognized as amajor
cause of nosocomial bacteremia and infections associated with invasive de-
vices, mechanical ventilation, burn wounds, or surgery in the immunocom-
promised and the immunocompetent host [1,2]. The worldwide emergence
of multidrug-resistant (MDR) nosocomial clones has added significantly to
the ominous prognosis of P aeruginosa infections. It has been reported
that MDR strains are associated with a threefold higher rate of mortality,
a ninefold higher rate of secondary bacteremia, a twofold increase in the
length of hospital stay, and a considerable increase in cost [3]. The high vir-
ulent potential of MDR P aeruginosa strains were also shown in current US
data in which greater mortality (30.7%) was observed in hospitalized patients
who received inadequate empiric therapy for bacteremia compared with
those who were given appropriate therapy (17.8%) [4].
Based on the worldwide prevalence of MDR strains of P aeruginosa and
the fact that no newer antipseudomonal agents are available, this article
aims to investigate therapeutic solutions for combating infections caused
by P aeruginosa, including MDR strains. The article focuses mainly on
colistin, the re-emerging old antibiotic that possesses prominent antipseudo-
monal activity in vitro and on doripenem, a newer carbapenem that seems to
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262 GIAMARELLOU & KANELLAKOPOULOUbe close to its global marketing [5,6]. Regarding older antipseudomonal an-
tibiotics that have been reviewed extensively, only newer aspects on their use
are considered in this article [7].Newer aspects on the efficacy of traditional antipseudomonal antibiotics
Currently available older antipseudomonal antibiotics include ticarcillin/
clavulanate, ceftazidime, aztreonam, cefepime, imipenem, meropenem, pi-
peracillin-tazobactam, the aminoglycosides, and ciprofloxacin. Because of
the versatility and the large size of P aeruginosa genome, various resistance
mechanisms can be present simultaneously, causing cross-resistance to sev-
eral antipseudomonal agents [8]. Specifically the production of penicillin-
ases, cephalosporinases, and carbapenemases represent the most common
underlying resistance mechanisms against b-lactams. The production of
the metallo–b-lactamases, which number 36, is particularly harmful because
they hydrolyzedwith the exception of aztreonamdall b-lactams, including
carbapenems [9]. Various efflux pumps, which remove several b-lactams
from the intracellular milieu, and the reduction in the number of porin
channels at the bacterial cell wall represent other important mechanisms
of resistance that are also responsible for collateral damage to the fluoroqui-
nolones. On the other hand, five plasmid–mediated acetylaces and
adenylaces plus ribosomal methylation are capable of modifying the amino-
glycosides and neutralizing their activity [10].
The increasing resistance rates of P aeruginosa strains to several antibi-
otics are expanding globally. In the United States, according to the NNIS
system, 33% of the isolates were found resistant to ciprofloxacin, 22% to
imipenem, and 30% to ceftazidime, which increased the period from 1997
to 2001 to 37%, 32%, and 22%, respectively [11]. Relevant figures for inten-
sive care unit (ICU) isolates derived from Europe are even worse, because
from 1990 to 1999, resistance to aminoglycosides reached 37% to 70%, re-
sistance to ceftazidime reached 57%, resistance to piperacillin-tazobactam
reached 53%, resistance to ciprofloxacin reached 56%, and resistance to
imipenem reached 52% [12]. Current resistance patterns of P aeruginosa
strains collected by the global surveillance study MYSTIC are shown in
Table 1 (http://www.mystic-data.org). It should be pointed out that Greece,
Brazil, the Czech-Republic, and Bulgaria possess the highest individual re-
sistance rates to carbapenems, probably indicating high consumption rates
of the latter antibiotics. Compared to imipenem, however, meropenem is
more potent and is active against up to one third of imipenem-resistant
strains, which indicates that a considerable percent of the strains should
have lost the OprD porin, which is influential mainly against imipenem
[13]. On the other hand, piperacillin and tazobactam seem to be less vulner-
able to resistance development in most countries and regions. Based on the
reported resistance surveillance data, it is evident that the current therapeu-
tic approach for P aeruginosa infections is limited [14].
Table 1
Global resistance surveillance of Pseudomonas aeruginosa isolated in the MYSTIC program: resistance rates to the indicated antimicrobial agent
Region
Gentamicin
2000–2006
Tobramycin
2000–2006
Pip/Tazo
2000–2006
Ceftazidime
2000–2006
Cefepime
2000–2006
Imipenem
2000–2006
Meropenem
2000–2006
Ciprofloxacin
2000–2006
Northern Europea 31.5–28.3 9.7–17.6 11.1–10.5 23.4–23.6 26.6–37.5 27.8–31.3 16.4–15.3 24.9–28.2
Southern Europeb 45.5–24.2 26.9–42.1 10.6–8.6 29.7–31.9 26.9–26.3 35.4–27.6 13–18 50–26.7
Eastern Europec 39.5–39.8 54.4–46.0 25.7–24.2 47.4–26.4 52.8–40.8 48–35.8 45.7–35.6 48.4–41.7
United States 18.4–15.8 8.1–10.1 13.7–11.4 17.4–18 29.8–25.8 19.1–19 13.3–13.5 26.4–26.1
Canada NA–30d NA–16.8 NA–16.2 NA–38.2 NA–31.3 NA–30.8 NA–22.5 NA–22.5
South Americae 65.2–49.2 65.2–49.3 23.9–34.5 49–44 31.2–55 38.1–54.8 11.9–49.5 63–56
Mexico 25–33.2 38.9–53.5 11.1–25.3 11.1–53.5 20–0 6.5–32.4 56–24 58.3–29.6
Hong–Kongd NA–13.2 NA–5.6 NA–1.6 NA–18.5 NA–29.4 NA–11.6 0.0 NA–15.8
Australiaf NA–13.2 NA–NA NA–7.9 NA–15.8 NA–9.1 NA–18.4 NA–7.9 NA–7.8
Susceptibility breakpoints (mg/mL): Amikacin %16, gentamicin %4, todramycin %4, piperacillin/tazobactam %64, ceftazidine %8, cefepime %8,
imipenem %4, meropenem %4, ciprofloxacin %1.
Abbreviations: NA, nonavailable; MYSTIC, Meropenem Early Susceptibility Test Information Collection Program.
a Belgium, Finland, Germany, Sweden, United Kingdom.
b Greece, Italy, Malta, Portugal, Spain, Switzerland.
c Bulgaria, Croatia, Czech Republic, Israel, Poland, Romania, Russia, Slovenia, Turkey.
d Refers to year 2005.
e Argentina, Brazil, Columbia, Peru, Venezuela.
f Year 2000 not included because of low numbers of strains.
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264 GIAMARELLOU & KANELLAKOPOULOUIn numerous studies, the application of pharmacokinetics/pharmacody-
namics (PK/PD) has enabled the enhancement of the antipseudomonal ac-
tivity of antimicrobials with in vitro activity at the susceptibility cut-off
points. For concentration-dependent antibiotics like the aminoglycosides
and the quinolones, the estimation of the maximum serum concentration di-
vided by the minimum inhibitory concentration (MIC) and the area under
the serum concentration-time curve divided by the MIC predict a successful
therapy. For time-dependent agents, such as the b-lactams, the percentage
of time that the drug concentration remains two to four times above the
MIC has helped to predict the probability of a successful clinical outcome,
whereas for both types of antibiotics, the PK/PD applications decreased re-
sistance development during therapy [15]. It seems that the dosages of anti-
pseudomonal antibiotics should be adapted to meet PK/PD criteria of
efficacy. In Table 2, some PK/PD target values for optimizing therapy
against P aeruginosa are described. Source models are mostly representedTable 2
Pharmacodynamic targets for successful treatment of Pseudomonas aeruginosa infections
PD Target Effect
Type of antimicrobial
Penicillins
Ticarcillin % t O MIC 100% Maximum
Piperacillin % t O MIC 40% Static
Cephalosporins
Ceftazidime % t O MIC 60%–70% Cidal
Serum levels 6.6  MIC Maximum
Cefepime 83%–95% of the dosing
interval O 4.3  MIC
Maximum
Carbapenems
Imipenem
and Meropenem
% t O MIC 22% Static
% t O MIC 100% Cidal
Meropenem Cmin/MIC O 6.2 (O 1.7
in combination with tobramycin)
Resistance
prevention
Aminoglycosides
Tobramycin
and Gentamicin
Cmax:MIC R 8; Cmax R 6 mg/mL
Amikacin Cmax:MIC R 8; Cmax R 24 mg/mL
Netilmicin Cmax:MIC R 8
Fluoroquinolones
Ciprofloxacin AUC:MIC R 125 Maximum
AUC:MIC R 100–157 Resistance
prevention
% t O MIC: percentage of the dosing interval that the drug concentration remains greater
than the MIC.
AUC, area under the serum concentration curve; Cmax, maximum serum concentration;
Cmin, minimum serum concentration.
Data from Burgess DS. Use of pharmacokinetics and pharmacodynamics to optimize
antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005;40(S2):
99–104.
265THERAPY OF MDR P AERUGINOSAby neutropenic mouse thigh and lung infections, mathematical modeling,
and in vitro time-kill curves, whereas relevant studies in humans are scarce
[15]. Recently, in patients with P aeruginosa ventilator-associated pneumo-
nia (VAP) and an APACHE-2 score of more than 17, an extended
(4-hour) infusion of piperacillin-tazobactam (n ¼ 41) versus intermittent in-
fusion (n ¼ 38) produced significantly less 14-day mortality rates (12.25%
versus 31.6%; P ¼ .04) and fewer days of stay in the ICU (21versus 38
days; P ¼ .02) [16]. On the other hand, meropenem, 2 g, every 8 hours
with a 3-hour infusion (in combination with an aminoglycoside) provided
the greatest likelihood of P aeruginosa coverage, probably also preventing
resistance development [17]. For the aminoglycosides, once-daily adminis-
tration, by maximizing peak levels, allows optimal efficacy and possibly min-
imizes toxicity. For the fluoroquinolones, it seems that the total daily dosage
is more important, whereas with current therapeutic schedules, MICs more
than 0.5 mg/mL increase the risk of failure and resistance development [15].
The need to maintain the traditional antibiotic combination of a broad-
spectrum antipseudomonal b-lactam plus an aminoglycoside is still contro-
versial. Two recent meta-analyses on infections caused by susceptible strains
showed that there was no advantage over monotherapy in terms of mortal-
ity, clinical efficacy, or prevention of resistance, whereas more adverse
effectsdespecially nephrotoxicitydwere observed in the combinations
[18,19]. The analysis of P aeruginosa bacteremia subgroups showed a signif-
icant survival benefit for the combination [19].Colistin
The emergence of MDR gram-negative bacilli, mainly of P aeruginosa
and Acinetobacter baumannii, in parallel with the lack of new antibiotics,
led to the revival of polymyxins, an old class of cyclic polypeptide antibiotics
that was discovered in 1947 and since 1950 has been on the market [14,20].
Colistin, which is produced by Bacillus colistinus, is identical to polymyxin E
and is available in two forms: colistin sulphate (tablets or syrup for bowel
decontamination and powder for topically treating skin infections) and
colistin methanesulfonate (CMS). It also appears under the names of colisti-
methate sodium, pentasodium colistimethanesulphate, and colistin sulfonyl-
methate. Throughout the world, various brand names of CMS are used by
different pharmaceutical industries (eg, Coli-mycin M in the United States,
Colomycin and Promixin in the United Kingdom). It should be pointed out,
however, that compared with colistin sulphate, CMS is less potent but also
less toxic [14,20].Mode of action: resistance mechanismsThe target of antimicrobial action of colistin in gram-negative bacteria is
the bacterial cell membrane, in which an electrostatic interaction between
266 GIAMARELLOU & KANELLAKOPOULOUthe cationic polypeptide (colistin) and the anionic lipopolysaccharide (LPS)
of the outer membrane is observed [21]. This leads to the displacement of
magnesium and calcium, which normally stabilize LPS, from the negatively
charged LPS, leading finally to an increase in the permeability of the cell en-
velope, leakage of cell contents, and eventually cell death [21]. The bacteri-
cidal efficacy of colistin is rapid in vitro. Studies with colistin-resistant
P aeruginosa have reported alterations at the outer membrane of the cell,
such as reduction in cell envelope Mg2þ and Ca2þ contents, lipid alteration,
and substitution of protein OprH for magnesium in the outer membrane
[22]. Despite the slow development of resistance, in Greece in 2005, among
MDR Klebsiella pneumonia strains (ESBL and VIM producers) derived
from ICU patients and belonging to six different clones, 16% were found
to be resistant to colistin, whereas after 2005 resistance mounted to 37%
[23,24]. Colistin has potent antiendotoxin activity; however, the significance
of the latter mechanism in humans is not clear [14].Antibacterial activityColistin is active in vitro against P aeruginosa, Aeromonas spp, Acineto-
bacter spp, Stenotrophomonas maltophilia, Escherichia coli, and Klebsiella
spp, including ESBL producers, Enterobacter, Citrobacter spp, Salmonella
and Shigella spp, Haemophilus influenzae, Legionella pneumophila, Borde-
tella pertussis, and several mycobacteria, including Mycobacterium tubercu-
losis [25]. Colistin is not active against gram-positive cocci or Proteus,
Providencia spp, Morganella morganii, Serratia spp, Vibrios, Burkholderia
cepacia complex, Burkholderia pseudomallei, and Edwardsiella spp. The
pathogenic Neisseria spp, Moraxella catarrhalis, Helicobacter pylori, and
Brucella spp and all anaerobic species are intrinsically resistant [14]. Com-
pared with colistin sulphate, CMS has inferior antibacterial activity. Cur-
rently it is not clear whether in vitro testing results with the sulphate
compound are suitable for predicting the in vivo activity of CMS [26].
The heterogeneity and variability in the composition of CMS and its insta-
bility in solution complicate studies of its antibacterial activity [26]. After
administration, CMS is converted, at least partially, to colistin base.
In 2007, the Clinical and Laboratory Standards Institute reported inter-
pretation of MIC for P aeruginosa susceptible strains indicated by MICs
2 mg/mL or less and resistant ones by MICs of 8 mg/mL or more with rele-
vant zones of inhibition of 11 mm or more and 10 mm or less for colistin
sulfate disks of 10 mg (Oxoid, Hampshire, UK) [26]. According to the Soci-
ete´ Franc¸aise de Microbiologie, a concentration of 2 mg/mL or less has been
selected as the susceptibility break point, whereas the British Society for An-
timicrobial Chemotherapy has selected a break point of 4 mg/mL or less [27].
It should be pointed out that correlation of agar dilution MICs, which is
considered the gold standard, with disk diffusion susceptibility testing
showed that the latter classical method is unreliable for detecting colistin
267THERAPY OF MDR P AERUGINOSAresistance. Interestingly, 81%, 79%, and 89% of resistant to colistin gram-
negative strains were falsely reported as susceptible when tested either by the
product insert guidelines or the British Society for Antimicrobial Chemo-
therapy and the Societe´ Francaise de Microbiologie suggested disk diffusion
methods, respectively [28]. MICs obtained by the Vitek-2 system are not re-
liable, with only agar dilution or E-test being highly recommended [29].
The in vitro interaction of CMS with rifampin has been evaluated against
pan–drug-resistant P aeruginosa strains, including colistin. Synergy was re-
ported in 11.8% to 41.7% of strains, depending on exposure time [30].Dosage schedules: pharmacokinetics and pharmacodynamicsCMS is administered intravenously, intramuscularly, intrathecally, or in-
halationally [14,20]. Parenterally and in patients with normal renal function,
CMS is given in the United States at a dose of 2.5 to 5 mg/kg/d (31,250–
62,500 IU/kg) divided into two to four equal doses (1 mg of colistin equals
12,500 IU). In the United Kingdom, it is given at a dose of 4 to 6 mg/
kg/d (50,000–75,000 IU/kg) in three divided doses for adults and children
with body weights of less than or equal to 60 kg and at a dose of 80 to
160 mg (1–2 million IU) every 8 hours for body weights of more than
60 kg. The Greek experience has proved that a higher dose of 3 million
IU (2.4 mg/kg) every 8 hours is safe [20]. The intrathecal and the intraven-
tricular doses are equal to 125,000 to 500,000 IU per day. By the inhalation
route, the recommended dosage ranges from 500,000 IU every 12 hours to 2
million IU every 8 hours [31]. In case of renal dysfunction, the dosage ad-
justment recommended by the manufacturers is as follows: for serum creat-
inine levels of 1.3 to 1.5, 1.6 to 2.5, or more than or equal to 2.6 mg/dL, the
recommended dosage of colistin administered intravenously is 160 mg (2
million IU) every 12, 24, or 36 hours, respectively. During hemodialysis
treatment, the recommended dose is 80 mg (2 million IU) after each session,
whereas in continuous venovenous hemodiafiltration patients, a dosage of 2
to 3 mg/kg every 12 hours has been recommended [5,14,26].
Because microbiologic assays are not accurate, recently two different high
performance liquid chromatography assays were developed that permit the
accurate estimation of colistin base or sulphate and CMS values in human
plasma and biologic fluids, respectively [5,32]. CMS is poorly absorbed by
the gastrointestinal tract. After the intravenous administration of 1.63 to
3.11 mg/kg every 8 hours of CMS to patients with cystic fibrosis (CF) at
steady state, levels in plasma at 1 hour ranged from 2.6 to 9.8 mg/mL,
whereas at 6 hours they were between 0.36 and 2.5 mg/mg [32]. In 12 patients
who had CF who received intravenous CMS at a dose of 160 mg (2 million
IU) every 8 hours (for patients with body weight of ! 50 kg) or 80 mg
(1 million IU) every 8 hours (for patients with body weight of ! 50 kg),
the mean ( SD) half-life of CMS was estimated as 125  5.2 min, whereas
the level of colistin sulphate as 251  79 min [32]. Mean ( SD) total body
268 GIAMARELLOU & KANELLAKOPOULOUclearance, mean ( SD) volume of distribution (Vd), and area under the
curve (AUC) of CMS were 2.0  0.5 mL/min/kg, 340  95 mL/kg, and
23.43 mg/h/mL, respectively [32]. In case of meningitis, the intravenous ad-
ministration of 1 million IU of CMS every 6 hours resulted in cerebrospinal
fluid levels that were equal to 25% of the simultaneous serum concentration
[31]. In patients with CF, CMS plus several of its metabolites are excreted
primarily by the kidney through glomerular filtration. Approximately
62.5% is excreted as unchanged drug in urine, whereas no biliary excretion
is reported in humans [26].
Colistin sulphate and CMS express their bactericidal activity as concen-
tration-dependent antibiotics; the latter effect seems to be related to the
AUC/MIC. Further PK/PD investigations are essential for this unknown
antibiotic [5,26,32].Clinical experienceIn total from 1999 until August 2005, eight retrospective studies in-
volved 335 patients without CF, among whom 264 (78%) represented
ICU patients and 186 (55%) suffered from pneumonia (50% as VAP),
who were given (with the exception of one study where polymyxin B was
given) intravenous CMS at a dose of 1 million to 3 million IU every 8
hours for 12 to 22 days [14,33–35]. In almost all patients at a rate close
to 50% either MDR P aeruginosa or MDR A baumannii were isolated in
relevant cultures. Colistin as a rule was given in combination with other
antibiotics, mostly with a carbapenem. Clinical cure rates ranged between
57% and 73% with mortality rates of 20% to 61.9% and 0% to 37% in-
cidence of nephrotoxicity. Clinical efficacy in pneumonia exceeding 50%
was comparable to previously reported rates of outcome with piperacillin,
imipenem, and ciprofloxacin.
In 2007, three retrospective studies were published, two of which referred
exclusively to monotherapy with colistin in the treatment of VAP due to co-
listin susceptible only P aeruginosa or A baumannii [36–38]. In a small sam-
ple size study, Rios and colleagues [36] did not find any difference in
mortality rate (51.6% versus 45.1%) of 31 patients with VAP caused by iso-
lates susceptible only to colistin who were treated with colistin monotherapy
compared to 30 patients with VAP caused by carbapenem-susceptible
strains who were treated with imipenem or meropenem. Appropriate em-
piric antimicrobial therapy in the carbapenem-susceptible group should
have contributed to the lower mortality rate observed in this group when
compared to patients who had not received appropriate therapy with under-
lying strains susceptible only to colistin (36.6% versus 70%, respectively,
P ¼ .014). It was concluded that VAP episodes susceptible only to colistin
can be treated effectively using colistin, whereas the MDR susceptibility pat-
tern of pathogens should be suspected in patients with previous VAP or prior
antibiotic use for more than 10 days preceding the current VAP episode.
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the efficacy of monotherapy with colistin, the latter was compared with
imipenem in VAP caused by colistin-susceptible (n ¼ 60) and carbape-
nem-susceptible (n ¼ 60) A baumannii (51.6% versus 61.7%) or
P aeruginosa (48.4% versus 38.3%). A favorable clinical response was ob-
served in 75% of the group susceptible only to colistin versus 71.7% in
the carbapenem-susceptible group (P ¼ .68) without difference in the time
to resolution of infectious parameters between the two groups. None of
the patients developed renal failure [37].
The effectiveness of colistin was studied retrospectively in 95 cancer pa-
tients diagnosed with infections caused by MDR P aeruginosa treated either
with colistin (n ¼ 31) or with at least one active antipseudomonal agent (a
b-lactam antibiotic or a quinolone) (n ¼ 64) [38]. In 13 patients, colistin was
given in combination with other antipseudomonal antibiotics; in 18 patients
it was given as monotherapy. Compared with the control group, patients in
the colistin group were more likely to have had nosocomial infections (87%
and 64%, respectively; P ¼ .02). Among all patients 45% and 37%, respec-
tively, were neutropenic, 68% versus 58% had an ICU stay during therapy,
and Pseudomonas infection or colonization within the previous year was re-
ported in 42% versus 48%. No difference in the incidence of clinical and mi-
crobiologic response (52% versus 31% and 48% versus 41%), relapse rate
(10% versus 11%), infection-related mortality (26% versus 17%), or overall
mortality (61% versus 47%) and nephrotoxicity (23% versus 22%) was ob-
served. Multiple logistic regression analysis showed that patients treated
with colistin were 2.9 times more likely than patients in the control group
to experience a clinical response to therapy, however (P ¼ .026). Particularly
in patients treated with colistin monotherapy, higher clinical and microbio-
logic responses were observed, which rendered colistin a useful or preferred
alternative therapy for MDR infections in cancer-neutropenic patients. A
major limitation of the study is the lack of evaluation of the time to initiate
adequate therapy, however.
Recently, the efficacy of inhaled polymyxin B was studied in 19 patients
with MDR gram-negative infections of the respiratory tract, 14 patients with
pneumonia, 13 of whom experienced failure with previous therapy with
intravenous polymyxin-B, and 5 patients with purulent tracheobronchitis
[39]. Inhaled polymyxin B (after an aerosolized b2-agonist) was given at
a dose of 500,000/IU twice a day in combination with the parenteral drug
for 4 to 25 days. Cure was recorded in 10 (53%) patients, with improvement
in 8 (42%) and failure in 1. All 5 patients with P aeruginosa tracheobronchi-
tis were successfully treated with monotherapy of inhaled polymyxin-B. Al-
though aerosolized delivery seems promising as a therapeutic adjunct, it
requires prospective evaluation and careful monitoring for side effects, resis-
tance development, and superinfections [39].
Most of the reported studies share common drawbacks, however. They
are mostly small and retrospective without definite designed protocols.
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gensdwere mostly given simultaneously with CMS, which confounded its
therapeutic efficacy. Deterioration of renal function could not be attributed
exclusively to CMS. Neurotoxicity could not be evaluated because most pa-
tients were mechanically ventilated. Variable dosing of colistin and treat-
ment duration were applied. Resistance development during and at the
end of the studies was not monitored. No study among the reported ones
referred to a large number of patients with pure P aeruginosa infections.
Usually the reported studies also include A baumannii as a pathogen, the vir-
ulent capacity of which greatly differs from that of P aeruginosa.
Although experience with CMS in P aeruginosa CNS infections is lack-
ing, the results reported in MDR A baumannii central nervous system infec-
tions in 14 patients were successful. Thirteen patients were cured after the
administration of CMS intravenously or intrathecally or both [40].Toxicity and adverse reactionsThe most common and important adverse effects of colistin reported in
the literature are nephrotoxicity and neurotoxicity [14,20]. Early experience
with CMS revealed an incidence of nephrotoxicity mounting to 20.2% that
was attributed mainly to acute tubular necrosis. Colistin nephrotoxic effect
is closely related to its mechanism of action because it increases the tubular
epithelial cell membrane permeability, which results in increased influx of
cations, anions, and water and leads to cell swelling and lysis. In contrast
to older information, recent data indicated that nephrotoxicity in ICU pa-
tients after CMS administration is lowerdranging from 0% to 36%
[14,20]. Safety data from 19 courses of prolonged intravenous CMS admin-
istration (mean duration 43.4 days, mean daily dosage 4.4 million IU, mean
cumulative dosage 190.4 million IU) indicated that the median creatinine
value increased only by 0.25 mg/dL, which returned close to baseline at
the end of therapy [41]. The reported discrepancies should be attributed
to the improvement in supportive care offered to seriously ill patients, the
possible avoidance of coadministering other nephrotoxic drugs such as ami-
noglycosides, the different definitions of nephrotoxicity, and different for-
mulations of colistin lacking colistin sulphate impurities that are more
nephrotoxic.
The incidence of neurotoxicity in earlier studies of colistin reached ap-
proximately 7%, with paresthesias being the main adverse events that
mounted for unknown reasons to almost 29% in patients who had CF
[14,20]. In addition to facial paresthesias, dizziness, weakness, vertigo, visual
disturbances, confusion, ataxia, neuromuscular blockade leading to respira-
tory failure and apnea have been reported. Only one study included pro-
spective electrophysiologic testing of 12 colistin recipients that showed
evidence of neuromuscular junction blockade, although findings consistent
with critical polyneuropathy were seen in 6 of the tested patients [33].
271THERAPY OF MDR P AERUGINOSAIntraventricular high-dose administration also may cause convulsions. It is
hoped that nephro- and neurotoxicity are dose dependent and reversible
[14,20].
In the case of aerosolized CMS, bronchoconstriction has been reported,
which is an adverse effect that can be prevented by the inhalation of b2-
agonists before CMS administration [20].Resistance developmentNone among the reported studies monitored resistance development to co-
listin during and at the end of therapy. Three recent studies investigated the
possibility of resistance development to colistin [24,42,43]. In a study byLand-
manand colleagues [42] in aNewYorkHospital after 4 years of increasingpur-
chases of colistin, P aeruginosa expressed 5% resistance rate. In a Greek ICU,
the emergence of colonization in 37% of patients with colistin-resistant
K pneumonia in bronchial and bowel floras (among those colonized with
K pneumonia strains) is of concern. The simultaneous occurrence of various
infections with colistin-resistant gram-negatives and breakthrough bacter-
emiaswith intrinsically resistant to colistinProteus andSerratia spp in patients
on treatment with colistin formore than 12 days, is certainly worrying [24]. On
the other hand, the emergence of K pneumoniae strains producing metallo-
b-lactamases in Greek ICUs since 2001 resulted in excessive empirical use of
colistin, which led to a cluster of multiclonal pan–drug-resistant Klebsiella
strains implicated in bacteremias, VAP, and soft tissue infections, mostly in
patients with prolonged administration of colistin (median 27 days) [43]. Hor-
izontal transmission through hands also was proved by repetitive extragenic
palindromic-polymerase chain reaction. The analysis of risk factors after
a Greek ICU outbreak with pan–drug-resistant P aeruginosa causing VAP re-
vealed that the sole independent predictors were the administration of colistin
for 13 days or more or the combined use of a carbapenem for more than 20
days [44]. The outbreak resolved after reduction in the days of therapywith co-
listin plus reinforcement of infection control measures.ConclusionsIt is evident that future studies with colistin necessitate (1) large prospec-
tive trials in MDR infections of ICU patients under well-designed protocols
and reliable susceptibility testing, (2) clarification in vivo of the possible ben-
efits of coadministering colistin with other antimicrobials, (3) evaluation in
VAP of nebulized colistin as single therapy or in combination with paren-
teral colistin to establish the optimal dosing regimen in ICU patients, (4)
better monitoring and elucidation of resistance mechanisms, and (5) larger
experience in the febrile neutropenic host. There is no doubt that we must
explore ways for maintaining the survival of colistin. It is evident that to es-
cape resistance, duration of therapy should be limited to less than 12 days,
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should be exploited, and hand hygiene should be strictly applied. Colistin
is not an ICU panacea to be prescribed casually but only under certain strict
indications, as in severe ICU infections with pathogens susceptible only to
colistin or empirically in ICU nosocomial sepsis of late onset in settings
with high prevalence of MDR isolates. Even then, de-escalation should be
prompt whenever culture results permit replacement with another antibiotic.
It is probable that these policies may keep colistin as a real frontier against
MDR gram-negative micro-organisms.Doripenem
Doripenem(S-4661) is anovelparenteral carbapenemwitha researchhistory
in international meetings since 1994. It was developed by Shionogi & Co, Ltd.
(Osaka, Japan), approved in Japan in July 2005, and launched in September
2005 [6]. Outside Japan, the rights were licensed to Peninsula Pharmaceuticals,
Inc. (Alameda, California) and acquired subsequently by Ortho-McNeil Phar-
maceutical, Inc. (New Brunswick, New Jersey). Doripenem is not listed on the
European Medicines Agency Web site (http://www.emea.eu.int).
The chemical structure of doripenem is almost identical to that of merope-
nem. Doripenem, like meropenem and ertapenem and unlike imipenem, has
a 1-b-methyl side chain, whereas in doripenem the dimethylcarbamoyl side
of meropenem has been substituted by a sulfamoylaminomethyl group. This
structure confers b-lactamase stability and resistance to inactivation by renal
dehydropeptidases. The new agent shares the bactericidal mechanism of
action of other b-lactams, particularly carbapenems, by targeting PBP1-3 [6].Antimicrobial activityDoripenem is characterized in vitro by spectrum and potency against
gram-positive cocci similar to imipenem and ertapenem, whereas against
gram-negatives it is mostly similar to meropenem and is two- to fourfold su-
perior to imipenem. Against wild-type P aeruginosa isolates, doripenem was
found to be two- and fourfold more potent than meropenem and imipenem,
respectively (MIC90 0.5 mg/mL versus 1 mg/mL and 2 mg/mL, respectively)
[45]. After testing 2137 bacterial isolates in vitro, among which were 150
P aeruginosa strains, the range of MICs, MIC50, and MIC90 for doripenem,
imipenem, and meropenem was determined as follows: 0.03 to 16 mg/mL,
0.25 mg/mL, and 1 mg/mL, 0.06 to 32 mg/mL, 1 mg/mL, and 2 mg/mL,
0.03 to 32 mg/mL, 0.25 mg/mL, and 4 mg/mL [46]. The results of the
latter study permitted the characterization of a ‘‘susceptible’’ category as
2 mg/mL or less, ‘‘intermediate’’ as 4 mg/mL, and ‘‘resistant’’ as 8 mg/mL
or more, with disc diffusion breakpoints of 21 mm or more for susceptible,
18 to 20 mm for intermediate, and 17 mm or less for resistant isolates.
273THERAPY OF MDR P AERUGINOSASimilar results were obtained against MDR P aeruginosa strains isolated
from patients who had CF with no difference between mucoid (No 200)
strains and nonmucoid (No 200) strains. Doripenem also was active against
15% to 20% of the strains resistant to imipenem and almost 40% of the
strains characterized as resistant to ceftazidime, cefepime, and aztreonam
[47]. Similarly among 34 carbapenem-resistant and MDR P aeruginosa
strains, the lowest rate of resistance (approximately 30%) was found for
doripenem, which indicated the possibility that infections caused by carba-
penem-resistant strains may be treatable with doripenem [48].
Doripenem did not show antagonism and demonstrated either addictive
effects or mild synergy when tested in vitro with daptomycin, levofloxacin,
linezolid, and vancomycin against gram-positives and with amikacin, levo-
floxacin, and trimethoprim-sulfamethoxazole against fermenting and non-
fermenting gram-negative bacteria [6].
Regarding the in vitro resistance selection potential of doripenem,mutants
seemed to be harder to select in vitro than with other carbapenems, and the
increases inMICs were smaller for the resistant mutants [49]. Single-step dor-
ipenem mutants were resistant only to carbapenems and had lost Opr D,
whereas multistep mutants had broader resistance, putatively including up-
regulated efflux mechanisms. Like other carbapenems, doripenem, loses its
activity against P aeruginosa isolates with metallo-b-lactamases enzymes
(IMP and VIM).Pharmacokinetics and pharmacodynamicsIn a phase I, double-blind trial, 24 healthy volunteers received one of
three dosing regimens of doripenem: a 4-hour infusion of 500 mg every 8
hours for 10 days (cohort A); a 6-hour infusion of 1000 mg every 12 hours
for 10 days (cohort B); or a 4-hour infusion of 1000 mg every 8 hours for 10
days (cohort C) [50]. In each cohort, six subjects received doripenem and
two received placebo. Steady state was achieved in all cohorts after admin-
istration of doripenem for 7 consecutive days. Doripenem serum half life
was in the range of 0.65 to 1.65 hours (mean, approximately 1 hour),
AUC was 40.2 mg/h/mL, creatinine clearance was in the range of 15 to 36
L/h with Vdss in the range of 19 to 56 L. The mean doripenem concentration
at steady state (Css) was approximately 3.3 mg/mL in cohorts A and B and
approximately 4.5 mg/mL in cohort C. Doripenem was excreted mainly by
the renal route (70%) [50]. As renal function decreased, serum half life
increased from 1 to 5 hours (severe renal impairment) to up to 9 hours
(end-stage renal failure). Dialysis reduced systemic doripenem levels by
48% to 62% [51]. Regarding the use of PK/PD target attainment analysis
and the Monte Carlo simulation results, it was predicted that 500 mg of dor-
ipenem administered over 1 hour every 8 hours would be effective against
bacterial strains with MICs less than 2 mg/mL, whereas less susceptible
strains would be treated with prolonged infusions [52].
274 GIAMARELLOU & KANELLAKOPOULOUClinical trialsDoripenem is developed in an intravenous formulation as 250-mg vials
and was launched in Japan, its first market, in 2005 [6]. An inhaled (nebu-
lized) formulation is in phase I development in the United Kingdom for
the treatment of CF-associated lung infections [53]. The drug is in phase
III pivotal trials in North and South America and in Europe [6]. A total
of six trials were conducted, including two each of complicated urinary tract
infections and pyelonephritis, complicated intra-abdominal infections, and
nosocomial pneumonia (including VAP) caused by various micro-organisms
with successful therapeutic results. In October 2004, the US Food and Drug
Administration granted fast-track status to doripenem for the treatment of
nosocomial pneumonia, including VAP [6].
In phase II studies in 55 patients with chronic respiratory tract infections,
doripenem in various doses resulted in promising clinical result in 95.2% of
patients, with bacteriological eradication in 87.5% [54]. The propensity of
Pseudomonas strains to develop resistance during therapy requires further
study, however. Pooled results from two phase III randomized, double-blind,
multicenter studies comparing 5–14 days of intravenous doripenem (500 mg
every 8 hours ) to intravenous meropenem (1 g every 8 hours ) in adults who
have complicated intra-abdominal infections recently became available as
a meeting poster presentation [55]. A switch to oral amoxicillin/clavulanate
after greater than or equal to nine doses of doripenem ormeropenemwas per-
mitted. A total of 962 patients in both studies were randomized; 486 patients
received doripenem and 476 patients received meropenem. The clinical cure
rates in the microbiologically evaluable population were 84.6% for doripe-
nem and 84.1% for meropenem (difference 0.5%; 95% CI, -5.5%–6.4%).
The microbiologic cure rates were 84.3% for doripenem and 84.5% for mer-
openem. The microbiologic cure rate for infections caused by P aeruginosa
was 85% for doripenem versus 75% for the comparator.Toxicity and adverse reactionsIn general, doripenem was well tolerated. The most common adverse
event was headache, which was observed in 33% and 50% of patients who
received 500 mg every 8 hours and 1000 mg every 8 hours, respectively, ver-
sus 13% in the placebo recipients [56]. Infection site erythema was frequently
reported [50], whereas gastrointestinal disordersdexpressed as nausea and
diarrheadwere reported in 3.7% and 2.5% of patients, respectively [54].
Somnolence and postural dizziness were also described at similar frequencies
[50]. There was no evidence of a dose response in any adverse event [50].ConclusionsBased on in vitro activity and the clinical outcome, it seems that doripenem
could play an important role in patients with serious nosocomial infections,
275THERAPY OF MDR P AERUGINOSAincluding ICU patients, particularly in hospital settings with high rates of
MDR gram-negative bacteria, includingP aeruginosa. The potential develop-
ment of in vivo resistance of doripenem should be carefully studied, however.Epilogue
There is no doubt that antipseudomonal antibiotic overuse and misuse
are strongly connected with the emergence of MDR P aeruginosa [57]. In
the effort to improve therapeutic results while preserving the power of anti-
biotics, several policies have been suggested and applied successfully (ie, re-
stricting or banning certain classes of antibiotics, cycling antibiotics,
performing surveillance cultures, determining risk factors that indicate the
presence of MDR P aeruginosa, using appropriate dosing and mode of ad-
ministration of antibiotics according to PK/PD indications, decreasing the
duration of therapy, applying de-escalation of antibiotics given empirically,
and obeying rules of hand hygiene) [1,14,58]. Approaching the officially pre-
dicted ‘‘End of Antibiotics’’ [57], it is certain that if physicians do not de-
crease the overuse and misuse of antibiotics, the emerging multidrug
resistance problem of P aeruginosa will worsen while the era of ‘‘The End
of Antipseudomonal Antibiotics’’ will become a nosocomial nightmare.References
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